Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramiro Garzon

Showing results (131-140 of 134) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 134 results.
Nature Communications|July 31, 2020
Author Correction: The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemiaDimitrios Papaioannou, Andreas Petri, Oliver M Dovey, et al.
Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
The Journal of Clinical Investigation|September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsPaolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Genome Research|May 5, 2010
Reprogramming of miRNA networks in cancer and leukemiaStefano Volinia, Marco Galasso, Stefan Costinean, et al.
Pageof 14

Showing results (131-140 of 134) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 134 results.
Nature Communications|July 31, 2020
Author Correction: The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemiaDimitrios Papaioannou, Andreas Petri, Oliver M Dovey, et al.
Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
The Journal of Clinical Investigation|September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsPaolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Genome Research|May 5, 2010
Reprogramming of miRNA networks in cancer and leukemiaStefano Volinia, Marco Galasso, Stefan Costinean, et al.
Pageof 14